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Summary. Bisantrene (NSC 337766) is an anthracenedicarbox- 
aldehyde hydrazone demonstrating a wide spectrum of  activity 
in animal tumor model systems with no evidence of  cardio- 
toxicity or alopecia, in contrast to doxorubicin. Thirty-three 
women with advanced adenocarcinoma of  the breast were 
treated with 260 mg/m 2 IV  every 3 weeks. All patients had 
received at least one prior combination chemotherapy regimen 
for metastatic disease and 32/33 were refractory to doxorubicin. 
Of  28 patients evaluable for response one had a partial response 
lasting 10 weeks and three patients had stable disease for 22, 22, 
and 9 weeks. The most significant toxicities were nonhemato- 
logic: nausea and vomiting (41%), phlebitic reactions (38%), 
hypotension, one fatal anaphylactic reaction, and the develop- 
ment o f  a 7th cranial nerve palsy during drug infusion. 
Hematologic toxicity, leukopenia, was dose-limiting but man- 
ageable without associated infections or bleeding. These results 
indicate that bisantrene in this dose and schedule is not a useful 
drug in heavily pretreated breast cancer patients. The incidence 
and severity o f  phlebitic reactions limited venous access and 
adversely affected patient compliance. Preliminary results of  
other phase H breast cancer trials indicate a similar spectrum of  
toxicity but suggest more significant antitumor activity even in 
patients previously treated with doxorubicin. Trials conducted 
in patients with minimal prior treatment and with bisantrene 
administered via central line appear warranted for definitive 
assessment o f  the activity o f  this agent in breast cancer. 
Introduction 
Bisantrene (NSC 337766) (CL 216,942) (9,10-anthracenedi- 
carboxaldehyde bis (4,5-dihydro-lH-imidazol-2-yl) hydra- 
zone) dihydrochloride) is an anthracenedicarboxaldehyde 
hydrazone synthesized by American Cyanamid Co. in the 
interest of developing anthracene derivatives with a spectrum 
of activity similar to doxorubicin but without dose-limiting 
cardiotoxicity. In preclinical testing significant antitumor 
activity was observed in a wide spectrum of animal tumor 
models, including the mouse P-388 and L-1210 stem cell 
leukemias, Leiberman plasma cell tumor, B 16 melanoma, 
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colon tumor26,  and Ridgeway osteogenic sarcoma [4]. 
Although the exact mechanism of action is uncertain, bisan- 
trene probably acts as a DNA-intercalating agent. In com- 
parison with doxorubicin, bisantrene was shown to be three 
and four times more potent an inhibitor of 3H-uridine and 
3H-thymidine incorporation into RNA and DNA,  respectively, 
in the L5178Y lymphoma tissue culture system. The cytotoxic 
activity was not cell cycle-phase-specific [4]. Animal toxicology 
studies showed no evidence of alopecia or cardiomyopathy [4, 
5, 9]. Significant antitumor activity against a number of tumors 
has been reported in the human tumor-cloning assay [1, 12]. 
Results of breast cancer specimens tested for both bisantrene 
and doxorubicin sensitivity have shown bisantrene sensitivity 
in doxorubicin-resistant specimens, suggesting the absence of 
cross resistance between these two agents [8]. In phase I - I I  
testing activity has been reported in renal cell carcinoma, 
breast carcinoma, and hepatocellular carcinoma [1 -  3, 6, 8, 11, 
13]. The dose-limiting toxicity was myelosuppression, predom- 
inantly leukopenia. Other side-effects included nausea and 
vomiting, phlebitis, hypotension, chills, urticarial reactions, 
and anaphylactoid reactions [1, 7, 10]. Based on this promising 
preliminary data the Cancer and Leukemia Group B initiated a 
phase II trial in women with advanced breast cancer. 
Materials and methods 
Thirty-three women with histologically confirmed adenocar- 
¢inoma of the breast were entered into the trial. Eligibility 
requirements included bidimensionally measurable disease, a 
performance score of 3 or less by CALGB criteria (0 = no 
impairment, 1 = ambulatory, 2 -- in bed less than 50% of 
waking hours, 3 -- in bed more than 50% of waking hours, 4 = 
bedridden), prior treatment with no more than two standard 
chemotherapy regimens and less than 550 mg/m 2 doxorubicin, 
expected survival of at least 8 weeks, adequate bone marrow 
reserve: WBC ~> 4,000/~i, platelets > 100,000/~1, no evidence 
of obstructive liver disease: bilirubin < 1.5 mg/dl, and normal 
renal function: serum creatinine < 1.5 mg/dl. Before entering 
the study all patients had a complete history and physical 
examination, chest roentgenogram, complete blood count 
(CBC) with differential and platelet count, serum creatinine, 
electrolytes, serum liver function tests, 12-lead electrocardio- 
gram and radionuclide left ventricular ejection fraction 
determination. Radionuclide liver and bone scans were 
obtained when clinically indicated. Patients with clinically 
evident cardiac disease or an ejection fraction less than 0.45 
were ineligible. 
The initial dose for all patients was 260 mg/m 2, diluted to a 
concentration of 0,1-0.5 mg/ml Dextrose in water (USP) 
infused over a period of no less than 2 h. Treatment was 
repeated every 3 weeks. Dose modifications were based on the 
lowest count recorded during the preceding cycle as follows: if 
the WBC > 3.000/~tl and platelets > 100,000/~tl bisantrene was 
increased to 280 mg/m2; with WBC < 1,500/~d or platelets < 
50,000/~tl the dose was reduced to 220 mg/m 2. Blood pressure 
was monitored at 15-rain intervals during drug administration 
and for 60 min after completion of drug administration. CBC 
and platelet count were repeated weekly; serum liver function 
tests, serum creatinine, and measurable disease parameters 
were assessed every 3 weeks. An adequate trial of bisantrene 
required objective progression of disease after at least two 
cycles (6 weeks) or rapid progression after one cycle at a dose 
producing leukopenia (WBC < 3,000/~tl). Response criteria 
were defined as: partial response (PR), a reduction of at least 
50% in the sum of the products of the greatest perpendicular 
diameters of all measurable disease for at least 4 weeks in the 
absence of new disease elsewhere; stable disease, objective 
regression of disease less than required for a PR or less than 
25% increase in any measurable lesion; progression, increase 
in the sum of the products of the greatest perpendicular 
diameters of any measurable lesion by 25% or the appearance 
of new areas of malignant disease. 
Results 
Patient characteristics are detailed in Table 1. All patients had 
received at least one prior chemotherapy regimen for metas- 
tatic disease and two patients had, in addition, received 
adjuvant chemotherapy. In 63% of the patients there were two 
or more organ sites of disease. 
Of the 33 patients entered on study, there were six 
inadequate trials, five due to drug toxicity. One patient 
experienced an anaphylactic reaction while receiving the 
second course of bisantrene and died of cardiogenic shock 12 h 
later. This patient had no prior history of cardiac disease. The 
first course of bisantrene had been well tolerated. Halfway 
through the infusion of the second course the patient became 
diaphoretic and hypotensive (palpable blood pressure of 60 
mm Hg), The bisantrene infusion was discontinued and the 
patient's blood pressure responded to IV normal saline, 
corticosteroids, and epinephrine. However, due to the fluids 
given to elevate her blood pressure, the patient went into 
pulmonary edema and required intubation. Several hours after 
stabilization the patient again became hypotensive. Blood 
pressure could not be restored despite maximal efforts at 
cardiopulmonary resuscitation. One patient developed an 
irreversible 7th cranial nerve palsy during infusion of the first 
dose of chemotherapy and was removed from study. Two 
patients with poor venous access developed edema of the arm 
after the first course of bisantrene infused via a peripheral vein. 
Both were taken off study by their physician although there 
was no clear progression of disease. One of these patients i n  
addition experienced hypotension during and after drug 
infusion. During the infusion the patient complained of 
dizziness and nausea. A change in blood pressure from 132/90 
before treatment to 80/70 mm Hg was recorded. The blood 
pressure responded to discontinuation of the infusion and the 
administration of hydrocortisone. The drug infusion was 
resumed and completed at a slower rate. However, 15 rain 
after completion of the infusion the patient again became 
symptomatic and a blood pressure of 106/72 was recorded. The 
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patient received IV fluids and the blood pressure recorded 
10 min later was 120/80. No further problems occurred during 
an additional 1 h of observation. A fifth patient refused to 
continue treatment after experiencing severe nausea, vomit- 
ing, and 'numb'  and 'cold' extremities after the first bisantrene 
Table 1. Patient characteristics 
No. evaluable for response a 28 
Median age (range) 54 (35-76) 
Median performance score (range) 1 (0-3) 
Prior chemotherapy 
Metastatic disease 100% 
Adjuvant 8% 
1 regimen 42% 
2 regimens 58% 
Average no. of cytotoxic drugs (range) 5.2 (3-7) 
Dominant disease site 
Soft tissue 48% 
Osseous 4% 
Visceral 48% 




4 or more 5 
Response 
Partial response 1 
Stable 3 
Progression 24 
a Includes one early death from progressive disease 
Table 2. Hematologic toxicity a 
No. of patients 
No. of adequate trials 27 
WBC (cells/~tl) 
2,000-3,000 11 
1,000 - 1,900 7 
< 1,000 1 
Platelets (cells/~tl) 
50,000-100,000 1 
< 50,000 0 
Hb decrease (g%) 
2-4 9 
a Lowest count recorded 
Table 3. Nonhematologic toxicity 
No. of patients 
No. of evaluable patients 32 






Fever and chills 2 
Neurotoxicity (cranial nerve palsy) 1 
Anaphylactic reaction (fatal) 1 
Alopecia 0 
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infusion. There was one early death from progressive disease 
prior to re-evaluation. This patient has been included as an 
evaluable failure to respond. 
Of the 28 patients evaluable for response to bisantrene, 18 
(65%) received at least two cycles. There was one PR, 
occurring after three cycles in a patient with soft-tissue disease. 
This patient received eight cycles of bisantrene administered 
via Hickman catheter and had a response duration of 10 weeks. 
Three patients had stable disease for 22, 22, and 9 weeks. Two 
of these patients had Hickman catheters placed after five cycles 
and continued to receive treatment until there was objective 
progression of disease after six and seven cycles, respectively. 
The third patient, while demonstrating objective tumor 
regression, although less than that required for PR, was 
removed from study after three cycles because of severe 
phlebitis. All other patients progressed. 
Hematologic toxicity in the 27 patients in whom the trial of 
bisantrene was adequate is detailed in Table 2. The dose was 
escalated in seven patients and reduced or delayed due to 
toxicity in four. Hematologic toxicity was manageable with no 
associated infections or bleeding episodes. Leukopenia (WBC 
< 3.000/~I) was recorded in 70% of patients. Nonhematologic 
toxicity in 32 patients is detailed in Table 3. Nausea and 
vomiting occurred in 13 (41%) patients, grade i or 2 in nine 
(28%), and grade 3 by CALGB criteria (more than two 
vomiting episodes per day) in four (13%) patients. Only one 
patient received all drug infusions through a Hickman 
catheter. Phlebitic reactions occurred in 12 of the remaining 31 
patients evaluable for nonhematologic toxicity. The onset of 
these reactions was observed up to 48 h after infusion and 
ranged from mild erythematous streaking along the vein to 
edema of the entire arm. Other significant toxicities have been 
detailed above. 
Discussion 
In this phase II trial of bisantrene for the treatment of 
advanced adenocarcinoma of the breast, only one major 
response was observed. This response result would preclude 
with 99% confidence a 15% response frequency with bisan- 
trene in this dose and schedule. More favorable results have 
been reported in manuscript or abstract form by other 
investigators using a similar dose and schedule of bisantrene. 
Osborne et al. [8] reported six responses (two complete, four 
partial) in 30 patients, 19 of whom had received prior 
doxorubicin. Two of the responders were in the doxorubi- 
cin-pretreated group. Responders had received fewer prior 
drugs and had a better average performance status than 
nonresponders. The primary toxicity was leukopenia. An 
anaphylactoid reaction occurred in one patient; and five of six 
patients who received drugs via peripheral veins developed 
phlebitis. Yap et al. [13] have reported a 22% response rate, 
nine partial responses in 40 evaluable patients all previously 
treated with doxorubicin. However, of 23 patients known to be 
refractory to doxorubicin only two responded, as against seven 
responses in 14 patients who were not known to be refractory. 
Granulocytopenia was the most frequently encountered tox- 
icity. Phlebitis occurred in all patients who received the drug 
via peripheral veins and one nonfatal acute anaphylactic 
reaction occurred. The Eastern Cooperative Oncology Group 
[3] observed two partial responses in 18 evaluable patients. 
Leukopenia, allergic reactions, and phlebitis were the 
dose-limiting toxicities. Cavalli et al. [2] have reported less 
encouraging preliminary results. One partial response was 
observed in 26 patients. These patients had received an 
average of six prior drugs and 50% of patients had been treated 
with doxorubicin. Leukopenia and phlebitis were noted as 
toxicities. 
The patient population in this CALGB trial had been 
heavily pretreated, with 57% refractory to two prior combi- 
nation chemotherapy regimens for metastatic disease and all 
but one patient previously treated with doxorubicin. The only 
major response occurred after three cycles of treatment. One 
other patient who was demonstrating tumor regression was 
taken off study after three cycles due to phlebitis. Although 
leukopenia was the dose-limiting toxicity as determined in 
phase I trials and the most fl'equently observed toxicity (70%) 
in this trial, nonhematologic toxicities limited drug adminis- 
tration in six patients: phlebitis, nausea and vomiting, cranial 
nerve palsy, hypotension, and one fatal anaphylactic reaction. 
Difficulties with venous access and a patient population whose 
disease was resistant to many conventional agents, including 
doxorubicin, are possible reasons for the low activity observed 
in this trial. Preliminary results of other trials confirm a 
significant incidence of phlebitis when bisantrene is adminis- 
tered via peripheral veins despite dilution of bisantrene to 
concentrations less than 0.5 mg/ml and slow infusion rates. 
Hypotension and 'anaphylactoid' reactions have been reported 
in up to 10% of patients receiving multiple courses of 
bisantrene [7] and therefore represent a significant degree of 
morbidity and warrant cautious attention to drug administra- 
tion. The preinfusion use of antihistamines and corticosteroids 
has been recommended, although benefit is uncertain since 
reactions have occurred in premedicated patients. However, 
bisantrene is well tolerated in most patients, producing only 
mild nausea and vomiting and no alopecia. Further trials of 
bisantrene, in patients with minimal prior treatment and with 
drug administered via central line, appear warranted to 
confirm its activity in breast cancer. 
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